KYVERNA THERAPEUTICS INC (KYTX)
Health Care · Clinical-stage immunology biopharmaceuticals · NASDAQ
Kyverna is a clinical-stage immunology biotech developing novel investigational therapeutics with no approved products and complete dependence on successful clinical trial outcomes.
What KYVERNA THERAPEUTICS INC does
Kyverna Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel treatments for immunological indications. The company has no approved products for commercial sale, has never generated product revenue, and is entirely dependent on the success of its investigational product candidates. The company is currently unprofitable and relies on external capital to fund its preclinical studies, clinical trials, and research and development programs.
Themes: ["immunology","clinical development","drug discovery","biopharmaceuticals"]
Fundamentals
- Price$9.81 as of 2026-07-09 close
- Market cap$602M as of 2026-07-10
- 1-year return+251.4% as of 2026-07-09 close
- Net margin-411.3% as of 2026-07-10
- ROE-81.9% as of 2026-07-10
- Debt / equity0.13 as of 2026-07-10
- Beta1.58 as of 2026-07-10
Key risks (from latest filing)
["Company has no approved products and no revenue history; substantial net losses expected to continue indefinitely","Requires substantial additional capital to fund operations; inability to raise funds could force delays or elimination of development programs","Clinical development is lengthy and expensive with uncertain outcomes; patient enrollment challenges, adverse events, or failed trials could delay or prevent regulatory approval and commercialization"]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.